Perspective Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Robert Burns has given his Buy rating due to a combination of factors that suggest a positive outlook for Perspective Therapeutics. Key catalysts are anticipated, including significant anti-tumor activity data from various cohorts expected between early 2026 and late 2027, which could enhance the company’s market position and investor interest.
Despite reporting a net loss for the third quarter of 2025, the company’s financial health remains robust with a substantial cash reserve projected to support operations into late 2026. The valuation analysis, employing a discounted cash flow methodology, indicates a favorable market value and a 12-month price target of $10 per share. However, Burns acknowledges potential risks such as negative clinical outcomes, regulatory hurdles, and competitive pressures, which investors should consider.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $13.00 price target.